Cobimetinib fumarate is a Small Molecule owned by F. Hoffmann-La Roche, and is involved in 77 clinical trials, of which 32 were completed, and 45 are ongoing.
Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal- related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2.
The revenue for Cobimetinib fumarate is expected to reach a total of $684m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cobimetinib fumarate NPV Report.
Cobimetinib fumarate Overview
Cobimetinib (GDC-0973 / RG7421 / Cotellic) acts as an anti neoplastic agent. It is formulated as film coated tablets and tablets for oral route of administration. Cotellic is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
The drug candidate is under development for the treatment of extracranial arteriovenous malformations (AVM), atypical teratoid rhabdoid tumor, hairy cell leukemia, chronic myelomonocytic leukemia, non-small cell lung cancer (first and third-line therapy), histiocytic disorders such as Langerhans cell histiocytosis and other histiocytic disorders such as juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD) and Rosai-Dorfman Disease (RDD)), craniopharyngioma, glioma, high-grade glioma, low-grade glioma, epithelial ovarian, fallopian tube, and primary peritoneal cancer, pediatric diffuse intrinsic pontine glioma, stages I-III non-small cell lung cancer with ALK, ROS1, NTRK, or BRAF v600E molecular alterations, pancreatic ductal adenocarcinoma, rhabdomyosarcoma, non-rhabdomyosarcoma, brenner tumor, soft tissue sarcomas Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor Rhabdoid tumors, including atypical teratoid/rhabdoid tumor (ATRT) NF1-associated tumor (including plexiform neurofibroma), schwannoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, relapsed and refractory acute myeloid leukemia, metastatic inflammatory breast cancer, HER-2 positive breast cancer and relapsed and refractory multiple myeloma. It was also under development for BRAF mutated metastatic melanoma (first line of therapy), endometrial cancer, metastatic colorectal cancer and metastatic triple negative breast cancer (first line of therapy). It is administered through oral and intravenous route.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Cobimetinib fumarate
|Highest Development Stage|